Follow us
EN
EN

One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

All news

Archive

✕
29 March 2019
8776
Scientists have described a spatial model of the spread of HIV

Scientists have described a spatial model of the spread of HIV

A group of scientists from the University of Friendship of Peoples (PFUR) presented a unique spatial model of the spread of the immunodeficiency virus in the human body. The mathematicians who published the results of their work in the journal Journal of Theoretical Biology ...
29 March 2019
8538
Implant-shaped naltrexone often helps HIV-positive overcome opioid dependence

Implant-shaped naltrexone often helps HIV-positive overcome opioid dependence

A team of specialists from the University of Pennsylvania, in collaboration with Russian scientists, was able to establish that a naltrexone implant placed under the skin of HIV-positive patients with opioid dependence can reduce the likelihood of relapse and have better ...
28 March 2019
9688
Transgender women partners form an independent risk group for HIV infection

Transgender women partners form an independent risk group for HIV infection

A study in the capital of Peru, Lima, a study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI2019), showed that transgender women’s sexual partners are mainly heterosexual polysexual men who rarely have sex with others men. Given this, ...
28 March 2019
8358
The effect of older ART on the redistribution of adipose tissue and the risk of CVD may be irreversible

The effect of older ART on the redistribution of adipose tissue and the risk of CVD may be irreversible

As follows from an article published last Friday in the AIDS journal, redistribution of adipose tissue in the body of HIV-positive people who have ever taken thymidine and / or didanosine (TA / ddI) or their analogues can persist patients' lives and act as a major risk ...
27 March 2019
11533
FDA Completes Two ART Guidelines

FDA Completes Two ART Guidelines

The United States Food and Drug Administration (FDA) last Tuesday, March 19, announced the completion of two regulations designed to describe guidelines for developing antiretroviral drugs for children and systemic drugs for the prevention of HIV infection (PrEP).
25 March 2019
10264
CDC: 40 percent of PLWH transmit HIV in the US

CDC: 40 percent of PLWH transmit HIV in the US

The U.S. Department of Health and Human Services (HHS) outlined a strategy to reduce by at least 90% the number of new HIV infections in the country by 2030. At the meeting, the results of a new report by the US Centers for Disease Control and Prevention (CDC) were announced, ...
22 March 2019
9938
Healthcare providers should talk about “U = U” to all PLWH

Healthcare providers should talk about “U = U” to all PLWH

Employees of medical organizations should inform all patients with HIV that if the viral load in their body is reduced to an undetectable level, there is no risk of sexually transmitted infection. This was stated by a group of authors in response to the widespread practice ...
20 March 2019
10788
DolPHIN-2: three quarters of HIV-positive women taking DTG from the third trimester gave birth to a healthy baby

DolPHIN-2: three quarters of HIV-positive women taking DTG from the third trimester gave birth to a healthy baby

At the international conference on retroviruses and opportunistic infections (CROI2019), the positive results of the research project DolPHIN-2, aimed at reducing the transmission of HIV from mother to child, were presented.
19 March 2019
9414
Descovy is not inferior to Truvada as a daily PrEP

Descovy is not inferior to Truvada as a daily PrEP

Descovy's daily supplement, which contains a newer version of tenofovir combined with emtricitabine, has a comparable protective effect with the traditional pre-exposure prophylaxis of HIV infection, including tenofovir and emtricitabine (Truvada), said Dr. Brad Hear of ...
18 March 2019
7078
The effectiveness of doravirine in combination with other ARVTs is not inferior to DRV + r / EFV

The effectiveness of doravirine in combination with other ARVTs is not inferior to DRV + r / EFV

#ART drug doravirin (DOR) as part of a 3-component therapy regimen HIV-1 is comparable in effectiveness to the combination of darunavir plus ritonavir (DRV + r) and efavirenza (EFV), follows from preliminary results of two ongoing clinical phase studies III DRIVE-FORWARD ...
We use cookies on this site to enhance your experience.
By clicking any button on this website you are giving your consent for us to set cookies.